Jupiter Neurosciences, Inc. JUNS PHARMA
Company Overview
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +148.39% |
| 6 Months: | -90.31% |
| 3 Months: | -82.22% |
| 1 Month: | -39.61% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)27.12 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 97.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | JUNS Jupiter Neurosciences, Inc. PHARMA | 3.08 | -0.16 | $4.06M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 18.65K |
| Gross Profit | - | - | - | - | - | - | - | - | - | 14.29K |
| Operating Income | - | - | -1.44M | -570.70K | -557.08K | -493.55K | -1.54M | -2.26M | -2.30M | -1.96M |
| Net Income | -1.75M | -832.61K | -1.77M | -634.10K | 313.12K | -591.02K | -1.53M | -2.25M | -2.29M | -2.06M |
| Diluted EPS | - | - | -0.07 | -0.02 | 0.01 | -0.02 | -0.05 | -0.07 | -0.07 | -0.06 |
| R&D Expense | - | - | 239.46K | 98.67K | 101.08K | 91.91K | 466.75K | 759.45K | 816.70K | 411.05K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | - | 0 | 21.80K |
| Gross Profit | - | - | 17.57K |
| Operating Income | -3.87M | -3.09M | -8.91M |
| Net Income | -4.78M | -2.44M | -8.64M |
| Diluted EPS | -0.18 | -0.08 | -0.25 |
| R&D Expense | 954.79K | 492.66K | 2.09M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 148.59K | 6.20M | 5.56M |
| Total Equity | -7.14M | -5.80M | 4.17M | -1.83M |
| Total Liabilities | - | 5.95M | 2.03M | 7.40M |
| Current Liabilities | - | 5.77M | 2.01M | 7.40M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -480.95K | -3.91M | -5.41M |
| Financing Cash Flow | 445.00K | 7.65M | 5.43M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | 80.6% |
| Operating Margin % | - | - | -40,873.2% |
| Net Margin % | - | - | -39,662.8% |
| ROE % | 82.5% | -58.5% | 471.9% |
| ROCE % | 68.8% | -73.7% | 486.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vestor Capital, LLC | 1.42% | 12.95K | $37.02K |
| 2 | Jane Street Group, LLC | 0.78% | 7.11K | $20.34K |
| 3 | Virtu Financial LLC | 0.34% | 3.08K | $8.82K |
| 4 | Geode Capital Management, LLC | 0.23% | 2.08K | $5.95K |
| 5 | Vanguard Capital Management LLC | 0.19% | 1.71K | $4.88K |
| 6 | Vanguard Fiduciary Trust Co | 0.12% | 1.12K | $3.21K |
| 7 | Xtx Topco Ltd | 0.05% | 437 | $1.25K |
| 8 | Tower Research Capital LLC (TRC) | 0.04% | 384 | $1.10K |
| 9 | Northern Trust Corporation | 0.04% | 338 | $966 |
| 10 | Stonex Group Inc. | 0.03% | 275 | $786 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for JUNS
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Aurora Cannabis Urged Shareholders to Reject Curaleaf’s Hostile Takeover Bid Tilray Expanded Global Cannabis Production as International Medical Demand Continues to Grow Key Takeaways; Psychedelic Sector Jupit…
Real Parkinson’s Disease Hope from Jupiter Neurosciences
By Mike Sheikh Parkinson’s Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. The market isn’t recognizing the story yet with…
Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva
Watch Fireside Chat Below, or Click HERE: IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. (Nasdaq: JUNS) Chairman, Chief Executive Officer and Co-founder Christer Rosén and Alison Silva, […]…
Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS)
The exclusive U. S. licensing deal adds a second clinical-stage CNS asset to Jupiter Neurosciences’ pipeline, expanding its development strategy beyond its lead Parkinson’s disease program.
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program JUPITER, FL, July 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neu…
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecule…
JUNS — Frequently Asked Questions
What is the current share price of Jupiter Neurosciences, Inc. (JUNS)?
As of 2026-09-19 21:16 PDT, Jupiter Neurosciences, Inc. (JUNS) trades at $3.08 on NasdaqCM. Its 52-week range is $1.24 to $135.00.
What is the market capitalisation of JUNS?
Jupiter Neurosciences, Inc. (JUNS) has a market capitalisation of $4.06M on NasdaqCM.
What is the P/E ratio of JUNS?
JUNS trades at a trailing price-to-earnings (P/E) ratio of -0.16. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -5.19.
Is JUNS a good stock to buy?
This page provides a data-driven analysis of Jupiter Neurosciences, Inc. (JUNS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.